AG-SILDENAFIL TABLET

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

SILDENAFIL (SILDENAFIL CITRATE)

Beschikbaar vanaf:

ANGITA PHARMA INC.

ATC-code:

G04BE03

INN (Algemene Internationale Benaming):

SILDENAFIL

Dosering:

25MG

farmaceutische vorm:

TABLET

Samenstelling:

SILDENAFIL (SILDENAFIL CITRATE) 25MG

Toedieningsweg:

ORAL

Eenheden in pakket:

4

Prescription-type:

Prescription

Therapeutisch gebied:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0136261001; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2022-11-15

Productkenmerken

_Pr_
_AG-SILDENAFIL_
_Page 1 of 43_
PRODUCT MONOGRAPH
PR
AG-SILDENAFIL
sildenafil (as sildenafil citrate) tablets
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
Date of Revision:
August 28, 2018
Angita Pharma Inc.
1310 Nobel Street
Boucherville, Quebec
J4B 5H3
SUBMISSION CONTROL NO.: 214622
_Pr_
_AG-SILDENAFIL_
_Page 2 of 43_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................
3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................
3
CONTRAINDICATIONS......................................................................................................
3
WARNINGS AND
PRECAUTIONS....................................................................................
4
ADVERSE
REACTIONS......................................................................................................
7
DRUG INTERACTIONS
.....................................................................................................
11
DOSAGEAND
ADMINISTRATION...................................................................................
14
OVERDOSAGE
....................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................
16
STORAGE AND
STABILITY..............................................................................................
19
SPECIAL HANDLING
INSTRUCTIONS...........................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................
19
PART II: SCIENTIFIC INFORMATION
............................................................................
20
PHARMACEUTICAL
INFORMATION......................................................